REPRINT: Good Laboratory Practice: Preventing Introduction of Bias at the Bench
- 1 February 2009
- journal article
- Published by SAGE Publications in International Journal of Stroke
- Vol. 4 (1), 3-5
- https://doi.org/10.1111/j.1747-4949.2009.00241.x
Abstract
As a research community, we have failed to demonstrate that drugs that show substantial efficacy in animal models of cerebral ischemia can also improve outcome in human stroke. Accumulating evidence suggests that this may be due, at least in part, to problems in the design, conduct and reporting of animal experiments, which create a systematic bias resulting in the overstatement of neuroprotective efficacy. Here, we set out a series of measures to reduce bias in the design, conduct and reporting of animal experiments modeling human stroke.Keywords
This publication has 14 references indexed in Scilit:
- Evidence for the Efficacy of NXY-059 in Experimental Focal Cerebral Ischaemia Is Confounded by Study QualityStroke, 2008
- Empirical Evidence of Bias in the Design of Experimental Stroke StudiesStroke, 2008
- How can we improve the pre-clinical development of drugs for stroke?Trends in Neurosciences, 2007
- Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysisBrain, 2007
- 1,026 Experimental treatments in acute strokeAnnals of Neurology, 2006
- Systematic Review and Metaanalysis of the Efficacy of FK506 in Experimental StrokeJournal of Cerebral Blood Flow & Metabolism, 2005
- Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With OutcomeStroke, 2004
- Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug DevelopmentStroke, 1999
- Quality of Full and Final Publications Reporting Acute Stroke TrialsStroke, 1998
- Why do all drugs work in animals but none in stroke patients? 2 Neuroprotective therapyJournal of Internal Medicine, 1995